Table 2.
First author | Year | Country | Ethnicity | Type of study | Subpopulation | Genotype | Number (n) | TC (mmol/l) | TG (mmol/l) | HDL-C (mmol/l) | LDL-C (mmol/l) | Genotyping method | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | SD | M | SD | M | SD | M | SD | |||||||||
Chen SN 1 [13] | 2005 | American | Mixed | Cohort | LCAS population | AA | 324 | 5.69 | 0.62 | 1.83 | 0.64 | 1.14 | 0.29 | 3.72 | 0.51 | Allelic discrimination assays |
AG + GG | 48 | 5.82 | 0.66 | 1.66 | 0.63 | 1.16 | 0.31 | 3.89 | 0.57 | |||||||
Chen SN 2 [13] | 2005 | American | Caucasian | Cohort | TexGen population | AA | 292 | NA | NA | NA | NA | NA | NA | 2.28 | 0.65 | Allelic discrimination assays |
AG + GG | 27 | NA | NA | NA | NA | NA | NA | 2.43 | 0.55 | |||||||
Evans D 1 [14] | 2006 | Germany | Caucasian | Cohort | Male group | AA | 190 | 6.05 | 1.4 | 1.39 | 0.45 | 1.16 | 0.31 | 4.29 | 1.34 | PCR-RFLP |
AG + GG | 26 | 6.57 | 1.48 | 1.55 | 0.44 | 1.2 | 0.29 | 4.65 | 1.37 | |||||||
Evans D 2 [14] | 2006 | Germany | Caucasian | Cohort | Female group | AA | 210 | 6.83 | 1.45 | 1.32 | 0.45 | 1.55 | 0.44 | 4.65 | 1.45 | PCR-RFLP |
AG + GG | 18 | 6.65 | 1.47 | 1.22 | 0.23 | 1.58 | 0.52 | 4.5 | 1.37 | |||||||
Scartezini M [15] | 2007 | UK | Caucasian | Cohort | NPHSII men | AA | 930 | 5.73 | 0.99 | NA | NA | 0.81 | 0.24 | 3.98 | 0.94 | PCR-RFLP |
AG + GG | 135 | 5.65 | 0.96 | NA | NA | 0.83 | 0.26 | 3.92 | 0.94 | |||||||
Polisecki E 1 [17] | 2008 | American | Caucasian | Cohort | Male group | AA | 2455 | 5.25 | 0.03 | NA | NA | NA | NA | 3.47 | 0.03 | Taqman |
AG + GG | 165 | 5.26 | 0.06 | NA | NA | NA | NA | 3.47 | 0.06 | |||||||
Polisecki E 2 [17] | 2008 | American | Caucasian | Cohort | Female group | AA | 2638 | 5.71 | 1.73 | NA | NA | NA | NA | 3.73 | 1.59 | Taqman |
AG + GG | 158 | 5.85 | 0.95 | NA | NA | NA | NA | 3.84 | 0.84 | |||||||
Hsu LA 1 [10] | 2009 | Taiwan | Asian | C-C | CAD group | AA | 541 | 5.14 | 0.96 | 1.59 | 1.3 | 1.42 | 0.37 | 3.02 | 0.85 | PCR-RFLP |
AG | 73 | 4.95 | 0.96 | 1.72 | 1.53 | 1.44 | 0.36 | 2.78 | 0.82 | |||||||
Hsu LA 2 [10] | 2009 | Taiwan | Asian | C-C | Control group | AA | 182 | 5.29 | 1.31 | 2.32 | 2.07 | 1.04 | 0.27 | 3.25 | 1.17 | PCR-RFLP |
AG | 20 | 5.28 | 0.74 | 2.48 | 1.4 | 1.07 | 0.33 | 3.41 | 0.6 | |||||||
Norata GD 1 [18] | 2010 | Italy | Caucasian | Cohort | PLIC study | AA | 1466 | 5.71 | 0.98 | 1.2 | 0.79 | 1.42 | 0.38 | 3.74 | 0.9 | Taqman |
AG + GG | 75 | 5.99 | 1.2 | 1.16 | 0.58 | 1.45 | 0.35 | 4.01 | 1.07 | |||||||
Norata GD 2 [18] | 2010 | Italy | Caucasian | Cohort | Ventimiglia study | AA | 728 | 4.76 | 0.99 | NA | NA | NA | NA | 3.02 | 0.86 | Taqman |
AG + GG | 48 | 4.89 | 0.98 | NA | NA | NA | NA | 3.23 | 0.87 | |||||||
Zeng J [19] | 2011 | China | Asian | C-C | CAD group | AA | 167 | 3.73 | 0.8 | 1.5 | 0.59 | 1.26 | 0.38 | 2.16 | 0.73 | PCR-RFLP |
AG + GG | 45 | 4.25 | 1.38 | 1.87 | 1.16 | 1.26 | 0.41 | 2.58 | 1.08 | |||||||
Meng YH [7] | 2011 | China | Asian | C-C | CAD group | AA | 146 | 4.41 | 0.72 | 0.99 | 0.62 | 1.48 | 0.51 | 2.22 | 0.63 | PCR-RFLP |
AG | 19 | 4.63 | 1.21 | 1.17 | 0.97 | 0.98 | 0.84 | 3.02 | 0.97 | |||||||
Aung LHH 1 [21] | 2013 | China | Asian | Cohort | non-drinker group | AA | 744 | 4.59 | 0.99 | 1.23 | 0.92 | 1.82 | 0.49 | 2.55 | 0.82 | PCR-RFLP |
AG | 41 | 5.01 | 1.25 | 1.09 | 0.78 | 1.86 | 0.51 | 2.68 | 0.86 | |||||||
Aung LHH 2 [21] | 2013 | China | Asian | Cohort | Drinker group | AA | 543 | 4.84 | 1.07 | 1.02 | 0.73 | 1.74 | 0.44 | 2.94 | 0.81 | PCR-RFLP |
AG | 24 | 4.55 | 0.64 | 1.1 | 0.58 | 1.63 | 0.5 | 2.69 | 0.44 | |||||||
Mayne J [20] | 2013 | Canada | Caucasian | Cohort | African Canadian population | AA | 192 | 5.56 | 1.14 | 1.59 | 0.77 | 1.2 | 0.4 | 3.64 | 1.01 | PCR + full exonic sequencing |
AG | 15 | 5.11 | 1.12 | 1.27 | 0.48 | 1.1 | 0.3 | 3.45 | 1.11 | |||||||
Slimani A 1 [8] | 2014 | Tunisian | African | C-C | CAD group | AA | 148 | NA | NA | 1.69 | 0.86 | 1 | 0.36 | NA | NA | PCR-RFLP |
AG + GG | 44 | NA | NA | 1.97 | 0.96 | 1.03 | 0.16 | NA | NA | |||||||
Slimani A 2 [8] | 2014 | Tunisian | African | C-C | IS group | AA | 90 | NA | NA | 1.58 | 0.75 | 1.35 | 0.4 | NA | NA | PCR-RFLP |
AG + GG | 24 | NA | NA | 1.47 | 0.58 | 1.04 | 0.19 | NA | NA | |||||||
Anderson JM 1 [22] | 2014 | Brazil | Caucasian | C-C | HC group | AA | 91 | 7.21 | 0.96 | 1.87 | 0.8 | 1.45 | 0.36 | 4.89 | 0.88 | Taqman |
AG + GG | 37 | 7.4 | 0.96 | 1.81 | 0.76 | 1.5 | 0.31 | 4.94 | 0.8 | |||||||
Anderson JM 2 [22] | 2014 | Brazil | Caucasian | C-C | NL group | AA | 131 | 4.47 | 0.47 | 0.91 | 0.32 | 1.53 | 0.36 | 2.53 | 0.47 | Taqman |
AG + GG | 40 | 4.5 | 0.49 | 0.95 | 0.3 | 1.47 | 0.26 | 2.59 | 0.47 | |||||||
Zhang L 1 [23] | 2014 | China | Asian | C-C | CAD group | AA | 291 | 4.07 | 1.16 | 1.82 | 0.79 | 1.37 | 0.16 | 2.29 | 0.77 | PCR-RFLP |
AG + GG | 125 | 4.49 | 1.31 | 1.87 | 1.09 | 1.31 | 0.25 | 2.5 | 0.74 | |||||||
Zhang L 2 [23] | 2014 | China | Asian | C-C | Control group | AA | 212 | 4.67 | 0.62 | 1.45 | 1.16 | 1.49 | 0.21 | 2.67 | 0.81 | PCR-RFLP |
AG | 45 | 4.53 | 0.33 | 1.37 | 0.88 | 1.4 | 0.21 | 2.63 | 0.8 | |||||||
Jeenduang N 1 [24] | 2015 | Thai | Asian | Cohort | Male group | AA | 132 | 5.54 | 1.3 | 1.46 | 0.84 | 1.32 | 0.35 | 3.66 | 1.13 | PCR-RFLP |
AG | 3 | 5.82 | 2.25 | 1.4 | 0.92 | 1.19 | 0.21 | 4 | 2.06 | |||||||
Jeenduang N 2 [24] | 2015 | Thai | Asian | Cohort | Female group | AA | 347 | 5.54 | 1.22 | 1.22 | 0.74 | 1.45 | 0.34 | 3.62 | 0.95 | PCR-RFLP |
AG | 13 | 5.99 | 0.94 | 1.01 | 0.35 | 1.49 | 0.23 | 4.04 | 0.94 | |||||||
Mo YQ [26] | 2015 | China | Asian | C-C | CAD group | AA | 87 | 4.48 | 0.81 | 0.97 | 0.58 | 1.49 | 0.47 | 2.12 | 0.72 | DNA sequencing |
AG | 13 | 4.56 | 0.97 | 1.05 | 0.89 | 0.97 | 0.73 | 3.01 | 0.83 |
C-C case–control, CAD coronary artery disease, IS ischemic stroke, NA not available, HC hypercholesterolemics, NL normolipidemics, UK United Kingdom, PCR-RFLP polymerase chain reaction- restriction fragment length polymorphism